Barclays Maintains Overweight on Phathom Pharmaceuticals, Lowers Price Target to $14

Benzinga · 1d ago
Barclays analyst Glen Santangelo maintains Phathom Pharmaceuticals (NASDAQ:PHAT) with a Overweight and lowers the price target from $18 to $14.